Form 8-K - Current report:
SEC Accession No. 0001193125-23-295027
Filing Date
2023-12-14
Accepted
2023-12-14 09:16:03
Documents
15
Period of Report
2023-12-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d598661d8k.htm   iXBRL 8-K 29595
2 EX-99.1 d598661dex991.htm EX-99.1 20928
7 GRAPHIC g598661g1214054010891.jpg GRAPHIC 3867
  Complete submission text file 0001193125-23-295027.txt   217404

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amgn-20231212.xsd EX-101.SCH 3286
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE amgn-20231212_def.xml EX-101.DEF 13059
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amgn-20231212_lab.xml EX-101.LAB 21633
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amgn-20231212_pre.xml EX-101.PRE 13766
9 EXTRACTED XBRL INSTANCE DOCUMENT d598661d8k_htm.xml XML 5499
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 231485772
SIC: 2836 Biological Products, (No Diagnostic Substances)